-
2025-523009-14-00
4
2025-12-16
Bronchiectasis with chronic pseudomonas aeruginosa colonization
-
2024-514500-14-00
5
2025-12-15
Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous
-
2025-523083-21-00
5
2025-12-08
PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor
-
2024-517261-16-00
9
2025-12-05
Advanced solid tumors
-
2025-521382-27-00
10
2025-12-04
Moderately to Severely Active Crohn's Disease
-
2025-521381-10-00
5
2025-12-03
Moderately to Severely Active Ulcerative Colitis
-
2024-512577-27-00
5
2025-12-02
Chronic kidney disease in paediatric patients
-
2024-519976-19-00
5
2025-11-26
Asthma with type 2 inflammation characterized by an eosinophilic pheno
-
2025-520927-26-00
5
2025-11-24
Metastatic Castration-resistant Prostate Cancer (mCRPC)
-
2024-511392-15-00
5
2025-11-20
HR+/HER2- advanced breast cancer
-
2025-521511-40-00
10
2025-11-18
metastatic non-small cell lung cancer
-
2024-518156-24-00
5
2025-11-10
Atopic Dermatitis
-
2024-520190-12-00
5
2025-11-10
Breast Cancer: triple negative breast cancer (TNBC) and hormone recept
-
2025-520566-22-00
5
2025-11-10
Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Ca
-
2024-519917-72-00
5
2025-10-29
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
-
2023-506296-97-00
5
2025-10-28
Moderate to Severe Plaque Psoriasis
-
2024-518365-10-00
5
2025-10-28
Previously Untreated Advanced or Metastatic Non-Squamous Non−Small Cel
-
2025-521556-35-00
1
2025-10-28
Narcolepsy
-
2024-517140-65-00
9
2025-10-23
Multiple Myeloma (MM).
-
2025-520564-17-00
5
2025-10-16
Hidradenitis suppurativa (HS)
-
2025-521188-11-00
5
2025-10-15
Type 2 diabetes
-
2024-516652-18-00
5
2025-10-10
Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
-
2024-514822-21-00
5
2025-10-02
Platinum-resistant Ovarian Cancer
-
2024-517866-40-00
4
2025-09-29
Moderate-to-severe Asthma